Sentinel lymph node biopsy in melanoma: Our experience over 8 years in a universitary hospital  by Bañuelos-Andrío, Luis et al.
CO
S
O
L
J
a
b
c
d
e
R
A
s
S
2
Birugía y Cirujanos. 2015;83(5):378--385
www.amc.org.mx www.elsevier.es/circir
CIRUGÍA  y  CIRUJANOS
Órgano de difusión científica de la Academia Mexicana de Cirugía
Fundada en 1933
RIGINAL ARTICLE
entinel  lymph  node  biopsy in melanoma:
ur experience  over  8  years  in  a universitary  hospital
uis Ban˜uelos-Andríoa,∗, Gil Rodríguez-Caravacab, José Luis López-Estebaranzc,
osé  Antonio Rueda-Orgazd, Fernando Pinedo-Moraledae
Unidad  de  Medicina  Nuclear,  Hospital  Universitario  Fundación  Alcorcón,  Madrid,  Spain
Servicio  de  Medicina  Preventiva,  Hospital  Universitario  Fundación  Alcorcón,  Madrid,  Spain
Servicio  de  Dermatología,  Hospital  Universitario  Fundación  Alcorcón,  Madrid,  Spain
Servicio  de  Cirugía  General,  Hospital  Universitario  Fundación  Alcorcón,  Madrid,  Spain
Servicio  de  Anatomía  Patológica,  Hospital  Universitario  Fundación  Alcorcón,  Madrid,  Spain
eceived 15  December  2014;  accepted  19  February  2015
vailable  online  7  December  2015
KEYWORDS
Cutaneous
melanoma;
Sentinel  lymph  node;
Lymphadenectomy;
Recurrences;
Predictive  factors
Abstract
Background:  Since  the  introduction  of  sentinel  lymph  node  biopsy,  its  use  as  a  standard  of
care for  patients  with  clinically  node-negative  cutaneous  melanoma  remains  controversial.  Our
experience  of  sentinel  lymph  node  biopsy  for  melanoma  is  presented  and  evaluated.
Material and  methods:  A  cohort  study  was  conducted  on  69  patients  with  a  primary  cutaneous
melanoma  and  with  no  clinical  evidence  of  metastasis,  who  had  sentinel  lymph  node  biopsy  from
October-2005  to  December-2013.  Sentinel  lymph  node  biopsy  was  identiﬁed  using  preoperative
lymphoscintigraphy  and  subsequent  intraoperative  detection  with  gamma  probe.
Results: The  sentinel  lymph  node  biopsy  identiﬁcation  rate  was  98.5%.  The  sentinel  lymph
node biopsy  was  positive  for  metastases  in  23  patients  (33.8%).  Postoperative  complications
after sentinel  lymph  node  biopsy  were  observed  in  4.4%  compared  to  38%  of  complications  in
patients who  had  complete  lymphadenectomy.
Conclusion:  The  sentinel  lymph  node  biopsy  in  melanoma  offers  useful  information  about  the
lymphatic dissemination  of  melanoma  and  allows  an  approximation  to  the  regional  staging,
sparing the  secondary  effects  of  lymphadenectomy.  More  studies  with  larger  number  of  patients
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and  long  term  follow-up  will  be  necessary  to  conﬁrm  the  validity  of  sentinel  lymph  node  biopsy
in melanoma  patients,  and  especially  of  lymphadenectomy  in  patients  with  positive  sentinel
lymph node  biopsy.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Biopsia  selectiva  del  ganglio  centinela  en  melanoma:  experiencia  durante  8  an˜os  en
un  hospital  universitario
Resumen
Antecedentes:  Desde  la  introducción  de  la  biopsia  selectiva  del  ganglio  centinela,  su  utilización
en pacientes  con  melanoma  cutáneo  y  ganglios  clínicamente  negativos  permanece  contro-
vertido.  Hemos  evaluado  nuestra  experiencia  en  biopsia  selectiva  del  ganglio  centinela  en
pacientes con  melanoma.
Material  y  métodos: Estudio  retrospectivo  observacional,  en  el  que  hemos  estudiado  una  mues-
tra de  69  pacientes  diagnosticados  de  melanoma  cutáneo  primario  sin  evidencia  clínica  de
afectación  metastásica,  a  los  que  se  realizó  biopsia  selectiva  del  ganglio  centinela  desde  octubre
de 2005  hasta  diciembre  de  2013.  El  ganglio  centinela  fue  identiﬁcado  mediante  una  linfogam-
magrafía  preoperatoria  y  posterior  detección  intraoperatoria  con  sonda  gammadetectora.
Resultados:  La  tasa  de  identiﬁcación  del  ganglio  centinela  fue  del  98.5%.  El  ganglio  centinela
fue positivo  en  23  pacientes  (33.8%).  Las  complicaciones  postoperatorias  después  de  la  biopsia
selectiva del  ganglio  centinela  fueron  observadas  en  el  4.4%,  frente  al  38%  de  los  pacientes
sometidos  a  linfadenectomía.
Conclusión:  La  biopsia  selectiva  del  ganglio  centinela  en  pacientes  con  melanoma  proporciona
valiosa información  sobre  las  vías  de  diseminación  linfática  del  tumor,  y  también  permite  una
aproximación  a  la  estadiﬁcación  regional  del  mismo,  evitando  los  efectos  secundarios  de  la
linfadenectomía.  No  obstante,  serían  necesarios  estudios  de  mayor  taman˜o  muestral  y  tiempo
de seguimiento  para  conﬁrmar  la  validez  de  la  técnica  de  la  biopsia  selectiva  del  ganglio  cen-
tinela en  pacientes  con  melanoma,  y  especialmente  de  la  linfadenectomía  en  casos  de  ganglio
centinela positivo.
©  2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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The  incidence  of  melanoma  has  greatly  increased  over  the
last  50  years.  In  2012  there  were  160,000  new  cases  of
melanoma  worldwide  (3600  in  Spain)  and  approximately
41,000  patients  worldwide  died  as  a  consequence  of  this
disease  (710  in  Spain).1
Since  its  introduction  in  19922 the  role  of  sentinel  lymph
node  biopsy  in  melanoma  care  remains  controversial  and  is
not  included  in  most  European  clinical  guidelines  for  the
management  of  melanoma.3 However,  this  procedure  has
become  a  habitual  practice  for  the  staging  and  treatment  of
≥  1  mm  clinically  node-negative  melanomas  or  melanomas
<  1  mm  thick  associated  with  factors  of  poor  prognosis.  This
threshold  aside,  the  predicted  number  of  positive  sentinel
lymph  nodes  is  too  low  to  justify  the  use  of  this  technique.
The  main  objective  of  sentinel  lymph  node  biopsy  in
melanoma  is  early  identiﬁcation  of  patients  with  clinically
occult  nodal  metastasis,  who  might  beneﬁt  from  a  lym-
phadenectomy.  Many  studies  have  shown  that  sentinel  lymph
a
p
tode  status  is  an  independent  prognostic  factor  in  rela-
ion  to  overall  survival  and  disease-free  survival  of  patients
ith  melanoma.4--6 Its  predictive  value  is  greater  than  the
sual  prognostic  factors,  such  as  Breslow  thickness,  Clark
evel,  the  presence  of  ulceration,  gender  and  age.7 Further-
ore,  the  information  obtained  regarding  the  lymph  status
s  essential  both  for  accurate  AJCC  staging6 and  decisions
egarding  possible  adjuvant  treatments.  However,  many
uthors  do  not  recommend  routine  use  of  this  technique,
asing  their  arguments  on  results  such  as  those  of  the  Mul-
icenter  Selective  Lymphadenectomy  Trial  (MSLT),8 which
id  not  show  any  signiﬁcant  differences  in  survival  between
atients  with  sentinel  lymph  node  biopsy  (and  immediate
ymphadenectomy  if  the  result  was  positive  for  metasta-
is)  and  those  patients  evaluated  only  by  observation  and
ith  lymphadenectomy  if  lymph  node  recurrence  resulted.
ther  retrospective  studies  have  revealed  similar  results
nd  the  outcome  of  sentinel  lymph  node  biopsy  and  of  lym-
hadenectomy  in  long-term  patient  survival  together  with
heir  therapeutic  contribution  is  currently  under  debate.9
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In  our  hospital  we  have  a  multidisciplinary  team  for  the
anagement  of  melanoma,  which  includes  the  following
ervices:  Nuclear  Medicine,  Dermatology,  General  Surgery,
athological  Anatomy  and  Oncology.  We  perform  between  5
nd  10  sentinel  lymph  node  biopsies  in  melanoma  patients
er  year  and  our  experience  spans  8  years  of  using  this
echnique.  In  cases  of  sentinel  lymph  node  metastasis  a  lym-
hadenectomy  of  the  affected  lymphatic  area  is  performed.
The  aim  of  our  study  was  to  evaluate  all  patients  with
elanoma  treated  in  our  hospital  using  sentinel  lymph  node
iopsy.
aterial and methods
n  observational  retrospective  study  was  conducted,  which
ncluded  all  patients  with  melanoma  on  whom  sentinel
ymph  node  biopsy  had  been  performed  in  the  Hospital  Uni-
ersitario  Fundación  Alcorcón  from  1st  October  2005  to  1st
ecember  2013.
The  selection  criterion  for  performing  sentinel  lymph
ode  biopsy  was  as  follows:  all  patients  with  ≥  1  mm  with
o  palpable  lymphatic  nodes  or  distant  metastasis.  Patients
ith  melanomas  <  1  mm  were  also  included  in  the  study  if
hey  presented  with  poor  prognostic  factors  such  as  Clark
evel  V  or  the  presence  of  ulceration/regression  in  anato-
opathological  analysis.
The  following  data  were  collected  for  each  of  the
atients:  gender,  age,  location  and  histological  type  of
rimary  lesion,  Breslow  thickness,  Clark  level,  location,
umber  and  status  of  sentinel  lymph  node,  lymphadenec-
omy  results  if  appropriate,  presence  of  ulceration,  mitotic
ndex,  presence  of  perineural  or  vascular  invasion,  pres-
nce  of  inﬂammatory  inﬁltration,  adjuvant  treatment,  side
ffects  of  sentinel  lymph  node  or  lymphadenectomy,  the
resence  of  (local  or  distant)  recurrence  and  survival.
ymphoscintigraphy  and  surgical  sentinel  lymph
ode technique
n  the  morning  of  surgery  lymphoscintigraphy  was  per-
ormed  by  injecting  37MBq  of  Tc99m-nanocolloid  human
erum  albumin  (Nanocoll®)  in  0.4  ml  intradermally  in  4-
uadrant  fashion  around  the  periphery  of  the  primary  lesion
r  biopsy  scar.
A  Philips  Skylight  conventional  2-headed  gamma  cam-
ra  with  low  energy  and  high  resolution  collimators  was
sed  to  obtain  the  images.  Dynamic  and  static  images  were
btained,  beginning  with  dynamic  images  5--10  min  after
njection  of  the  radiotracer  and  obtaining  static  images
very  20--30  min  thereafter  until  the  sentinel  lymph  node
as  visualised.
Surgery  took  place  the  same  morning  and  for  the  intra-
perative  location  of  the  sentinel  lymph  node  a gamma
robe  was  used  (Europrobe®,  Eurorad,  Strasbourg,  France),
andled  by  an  experienced  nuclear  medicine  physician.  All
odes  presenting  with  radioactive  activity  measured  by  the
amma  probe  as  larger  than  10%  of  the  node  with  greater
ctivity  ex  vivo  were  removed;  all  measurements  were  taken
er  second.  All  extirpated  nodes  were  placed  in  recipi-
nts  for  individual  examination.  A  thorough  search  for  any
adioactive  activity  in  the  surgical  site  was  carried  out  to
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nalise  the  procedure  and  once  it  had  been  conﬁrmed  that
o  deposit  activity  exceeded  10%  of  the  sentinel  lymph  node,
he  procedure  was  terminated.
natomopathological  analysis  of  the  sentinel  lymph  node
istological  analysis  involved  resecting  the  node  as  a  whole
y  2  mm  cross-section  cuts  which  were  then  dyed  using
aematoxylin-eosin  and  immunohistochemistry  staining  was
erformed  (S100,  HMB45,  MelanA).
urgical  and  adjuvant  treatment
ymphadenectomy  was  performed  on  patients  with  posi-
ive  sentinel  lymph  nodes  if  baseline  patient  conditions
llowed  it.  Adjuvant  treatment  with  interferon  was  offered
o  patients  with  stage  IIB  melanoma  with  positive  resected
entinel  lymph  nodes.
ollow-up
atient  follow-up  consisted  of  a  thorough  clinical  examina-
ion  in  the  Dermatology  unit  once  a  month  for  3  months
nd  then  every  6--12  months,  depending  on  the  patient’s
ondition,  for  an  indeﬁnite  period.  Disease  recurrence  and
urvival  status  was  obtained  from  the  computerised  clinical
ecords  of  the  Hospital  Universitario  Fundación  Alcorcón.
tatistical  analysis
tatistical  analysis  was  based  on  Pearsons  2 test  or  the
xact  Fisher  test  for  qualitative  data  analysis,  and  on  the
tudent  t-test  for  quantitative  analysis,  and  log-rank  anal-
sis.  Logistic  step-by-step  regression  analysis  was  used.
ccess  7.0  was  used  for  data  management  and  mathematical
alculations  were  made  using  the  SPSS  20.0  statistical  pro-
ramme  for  Windows.  The  signiﬁcance  level  was  determined
t  P  <  0.05.
esults
rom  October  2005  to  December  2013,  sentinel  lymph  node
iopsy  was  performed  on  69  patients  with  melanoma.  42
ere  female  (60.8%)  and  27  were  male  (39.2%).  The  mean
ge  of  patients  was  58.4  year-old.  Clinical  and  histological
haracteristics  are  shown  in  Table  1.
The  rate  of  overall  identiﬁcation  of  the  sentinel  lymph
ode  was  98.5%  (68  patients).  In  one  patient  who  presented
ith  a  tumour  in  the  left  breast  no  lymphatic  migration  was
etected  on  the  radiotracer  in  the  lymphoscintigraphy  prior
o  surgery  nor  were  any  sentinel  lymph  nodes  detected  intra-
peratively.  A  total  of  164  lymph  nodes  were  resected,  the
ean  number  of  sentinel  lymph  nodes  removed  being  2.37.
n  33%  of  cases  only  one  sentinel  lymph  node  was  removed,
ith  detection  of  the  node  in  the  following  areas:  unilateral
xilla  (33  cases,  47.8%),  bilateral  axillae  (one  case,  1.4%),
nilateral  groin  (27  cases,  39.1%),  bilateral  groins  (one  case,
.4%),  bilateral  groins  and  bilateral  axillae  (2  cases,  2.9%),
nilateral  head  and  neck  area  (3  cases,  4.3%),  bilateral  head
nd  neck  area  (2  cases,  2.9%).  The  drainage  area  for  limb
elanomas  was  always  homolateral.  Drainage  to  multiple
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Table  1  Clinico-pathological  sample  factors.
Total  SLN  positive  SLN  negative  p  OR
Number  69  23  (33%)  45  (66%)
Gender
Male 27  (39.2%)  7  (30.4%)  20  (44.4%)  0.5  (0.2--1.5)
Female 42  (60.8%)  16  (69.6%)  25  (55.5%)
Mean age  58.4  ±  17.2  58.6  ±  17.7  57.6  ±  17.7  0.2  2.62  (0.5--13.3)
Location
Trunk 34  (49.3%)
UL 7  (10.1%)
LL 18  (26.1%)
Acral  7  (10.1%)
Head  and  neck  3  (4.3%)
Type
Superﬁcial  dissemination  38  (55.1%)
Nodular  18  (26.1%)
Acral  lentiginous  7  (10.1%)
Others  6  (8.69)
Breslow
Mean  (mm) 2.83  ±  2.70 3.77  ±  3.4 2.36  ±  2.1 0.0023
T1 (0--1  mm)  16  (23.5%)  2  (8.7%)  14  (31.1%)
T2 (1.01--2  mm)  23  (32.4%)  7  (26.1%)  16  (35.6%)  2.62  (0.45--15.1)
T3 (2.01--4  mm)  14  (20.6%)  9  (39.1%)  5  (11.15)  12.6  (1.99--79.4)
T4 (>  4  mm)  16  (23.5%)  6  (26.1%)  10  (22.2%)  4.2  (0.69--25.2)
Clark level  0.0028
Level I  0  0  0
Level II  5  (7.4%)  0  5  (11.1%)
Level III  26  (38.2%)  5  (21.7%)  21  (46.75)  2.8  (0.13--58.98)
Level IV  34  (50%)  16  (69.9%)  18  (40%)  9.8  (0.50--191.26)
Level V 4  (4.4%)  2  (8.7%)  2  (2.2%)  18  (0.53--627.70)
Ulceration  0.415
Yes 25  (35.2%)  10  (39.1%)  15  (33.3%)
No 44  (64.7%)  14  (60.8%)  30  (66.6%)
Vascular/perineural  invasion
Yes  4  (5.8%)
No 65  (94.2%)
Inﬂammatory  inﬁltrate
Not  inﬁltrated  8  (11.6%)
Mild  23  (33.3%)
Moderate  16  (23.2%)
Intense  12  (17.4%)
Unknown  10  (14.5%)
Miotic  rate
≤ 5  46  (66.7%)
> 5  21  (30.4%)
Unknown  2  (2.9%)
Adjuvant  treatment
Yes  12  (17.4%)
No 54  (78.3%)
Unknown  3  (4.35%)
SLN: sentinel lymph node; LL: lower limbs; UL: upper limbs; OR: odds ratio; p: statistical signiﬁcance.
382  
Table  2  Multivariate  analysis  of  clinico-pathological  fac-
tors for  predicting  sentinel  lymph  node  involvement.
Clinico-pathological  factors  OR  (CI  95%)  p
Gender  0.42  (0.36--5.07)  0.502
Age >  40  U  0.999
Breslow  >  2  mm  1.96  (0.12--3.0)  0.627
Clark >  III  1.72  (0.12--24.2)  0.688
Ulceration  0.97  (0.09--9.62)  0.984
SLN: sentinel lymph node a; CI: conﬁdence interval; U: unknown;
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ode  ﬁelds  was  present  in  5  cases  (7.1%),  all  of  which  were
rom  dorsal  melanomas.
Of  the  68  patients  with  sentinel  lymph  nodes,  23  (33.8%)
ested  positive  for  metastasis.  With  regards  to  the  pre-
ictive  factors  of  metastatic  involvement  of  the  sentinel
ymph  node,  although  an  increase  in  risk  relating  to  the
roportional  involvement  of  the  Beslow  thickness  and  Clark
evel  was  observed,  no  statistical  signiﬁcance  was  found  in
ither  the  univariate  (Table  1)  or  the  multivariate  analysis
Table  2).
Lymphadenectomy  was  performed  on  78%  (18  out  of
3  patients)  of  the  patients  with  positive  sentinel  lymph
ode  results.  5  patients  with  positive  sentinel  lymph  node
esults  were  not  indicated  for  lymphadenectomy  due  to
aseline  patient  conditions  and  no  local  or  distant  recur-
ence  occurred  in  any  of  them.  Only  2  of  the  18  patients
11%)  on  whom  lymphadenectomy  was  performed  presented
ith  metastasis  to  other  lymph  nodes,  with  a  Breslow  thick-
ess  of  15.2  mm  and  2.77  mm,  respectively.  Of  patients  with
ositive  sentinel  lymph  node  results,  47%  were  treated  with
igh-dose  interferon  alfa2b  for  a  year  (Kirkwood  guideline).
ne  patient  (4.6%)  with  negative  sentinel  lymph  node  results
ut  with  negative  prognostic  factors  (stage  IIb)  was  treated
ith  interferon  alfa2b.
Mean  patient  follow-up  was  for  a  95  month  period  (ran-
ing  between  7  and  100  months).  Two  follow-up  cases
D
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Table  3  Analysis  of  recurrences  and  death  depending  on  the  stat
Total  SLN  positiv
SLN  status  66  22  (33.3%)  
Locoregional  recurrence  5
Yes  3  (13.6%)  
No 19  (86.3%)  
Distant recurrence  6
Yes  2  (9%)  
No 20  (91%)  
Overall recurrence  11
Yes  5  (22.7%)  
No 17  (77.3%)  
Death 3
Yes  1  (4.3%)  
No 22  (95.7%)  
SLN: sentinel lymph node; OR: odds ratio.L.  Ban˜uelos-Andrío  et  al.
ere  abandoned,  one  which  presented  with  positive  sen-
inel  lymph  node  results  and  the  other  negative.  There  were
1  cases  of  recurrence  (16.6%),  5  on  a  locoregional  level
nd  6  on  a  distant  level.  In  the  patient  group  with  positive
entinel  lymph  node  results,  5  (22.7%)  of  the  22  patients
xperienced  recurrence,  3  on  a  local  level  and  2  on  a  dis-
ant  level.  In  the  patient  group  with  negative  sentinel  lymph
ode  results  6  patients  (13.63%)  experienced  recurrence,  2
n  a local  level  and  4  on  a  distant  level,  which  determined
 false  negative  rate  of  9.5%  (false  negative  considered  to
e  the  presence  of  a  local  recurrence  in  patients  with  nega-
ive  sentinel  lymph  node  results).  Notwithstanding,  if  we
lso  included  those  patients  who  had  experienced  a  dis-
ant  recurrence  presenting  with  negative  sentinel  lymph
ode  results,  the  false  negative  rate  would  increase  up  to
3.6%.  Of  the  18  patients  with  positive  sentinel  lymph  node
esults  who  underwent  lymphadenectomy,  3  (16%)  experi-
nced  local  level  recurrence.  In  our  sample,  although  there
s  a  percentage  variance  in  recurrence  between  patients
ith  positive  sentinel  lymph  node  results  to  those  with  the
egative  sentinel  lymph  node  results  (OR  =  1.8;  Table  3),  no
tatistical  signiﬁcance  occurred  here.
Overall  mortality  of  the  sample  was  5.79%;  there  were  3
eaths  (4.3%)  caused  by  melanoma,  one  in  the  group  with
ositive  sentinel  lymph  node  results  (mortality  rate  of  4.3%)
nd  the  other  2  in  the  group  with  negative  sentinel  lymph
ode  results  (mortality  rate  of  4.4%).
Post-operative  complications  from  sentinel  lymph  node
iopsy  were  observed  (seroma,  infection)  in  4.4%  (3/68)
f  patients.  This  compared  with  the  complications  in  38%
7/18)  of  those  patients  with  positive  sentinel  lymph  node
esults  who  underwent  lymphadenectomy  (lymphoedema,
ymphocele  seroma,  infection)  (OR  =  0.07;  P  =  0.0005).  These
ifferences  were  statistically  signiﬁcant.iscussion
n  our  study  the  percentage  of  positivity  of  the  sentinel
ymph  node  was  33.8%,  which  is  above  that  of  other
us  of  the  sentinel  lymph  node.
e  SLN  negative  OR
44  (66.6%)
2  (4.5%)  3.3  (0.51--21.50)
42  (95.4%)
4  (9%)  1  (0.16--5.93)
40  (90%)
6  (13.63%)  1.8  (0.49--6.95)
38  (86.37%)
2  (4.4%)  1.023  (0.08--11.91)
43  (95.6%)
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studies  where  it  ranged  between  15%  and  23%.6,8,10--12
Of  those  patients  who  underwent  lymphadenectomy,  sub-
sequent  to  a  positive  sentinel  lymph  node  result,  11%
presented  with  other  non-sentinel  lymph  node  involvement.
This  result  was  comparable  to  other  series  where  the  per-
centage  ranged  from  7.8%  to  33%.5,6,13 The  low  incidence
of  positivity  in  non-sentinel  lymph  nodes  removed  in  lym-
phadenectomy  is  notable  in  our  study  (11%),  and  in  other
studies,  which  may  indicate  that  this  procedure  may  be
unnecessary  in  patients  with  thin  melanomas,4,14,15 showing
that  metastasis  in  these  patients  is  exclusively  conﬁned  to
the  sentinel  lymph  node.
Regarding  predictive  factors  of  sentinel  lymph  node
involvement,  we  found  no  statistical  signiﬁcance  in  the
univariate  analysis  for  Beslow  thickness  or  Clark  level,  in
contrast  to  other  studies.16,17 We  did,  however,  observe
a  tendency  for  an  increase  in  the  OR  for  metastasis
involvement  of  the  sentinel  lymph  node  when  the  Bres-
low  thickness  of  Clark  level  increased.  It  is  highly  probable
that  the  sample  size  was  insufﬁcient  for  any  statistical
signiﬁcance.
The  prognostic  value  of  the  Clark  level  for  the  pres-
ence  of  positive  sentinel  lymph  node  melanoma  has  been
stated  in  other  studies.18,19 Analysis  of  previously  pub-
lished  studies  reveals  that  the  cutting  off  levels  of  the
Clark  index  used  vary  greatly,  hindering  the  comparison
of  results  and  no  optimum  Clark  level  has  been  estab-
lished  for  predicting  the  presence  of  positive  sentinel  lymph
nodes.2
In  our  study  we  found  there  was  no  signiﬁcant  rela-
tionship  between  ulceration  and  sentinel  lymph  node
involvement,  in  contrast  to  other  series,  in  which  ulcer-
ation  is  negatively  associated  with  survival  in  all  Breslow
melanoma  subgroups,21 with  the  result  that  it  is  included  in
the  AJCC’s  TNM  classiﬁcation  from  its  sixth  edition.  How-
ever,  Sondak  et  al.22 found  no  association  between  the
presence  of  ulceration  and  a  positive  sentinel  lymph  node
result.  They  attribute  this  to  the  different  possible  causes
of  ulceration  and  to  the  error  which  may  induce  its  presence
on  measuring  Breslow  tumour  thickness.
Age  and  gender  variables  were  not  signiﬁcant  in  the  uni-
variate  analysis;  age  has  been  a  subject  for  debate  in  several
studies18,19,22 and  several  studies  detected  less  lymph  node
incidence  in  older  patients  despite  them  having  a  lower
disease-and  survival-free  period.18 Moreover,  the  relation-
ship  between  gender  and  the  result  of  the  sentinel  lymph
node  biopsy  has  not  been  established,  with  some  studies
showing  a  higher  number  of  positive  sentinel  lymph  nodes
in  males21,23 and  others  which  did  not.18,19,22 In  our  study
females  presented  with  a  higher  percentage  of  sentinel
lymph  nodes  but  this  outcome  was  not  statistically  signif-
icant.
No  statistically  signiﬁcant  differences  were  found  for  any
of  the  variables  analysed  in  the  multivariate  analysis.  This
result  could  be  due  to  several  factors:  the  sample  size,  the
scarcity  of  events  and  also  because  many  histological  varia-
bles  such  as  Breslow  density,  Clark  levels  and  ulceration  are
correlated  with  one  another,  which  may  lead  to  possible
confusion.20
We  found  2  cases  in  which  the  sentinel  lymph  node
was  negative  and  local  lymph  node  recurrence  occurred,
s
w
c383
iving  rise  to  a  false  negative  rate  of  9.5%,  that  falls  within
he  range  observed  in  other  studies  of  between  4%  and
2%.5,12,24 These  false  negatives  may  be  associated  with
ifferent  factors:  the  learning  curve  of  the  technique,25
he  alteration  of  lymphatic  dissemination  routes  associated
ith  primary  tumour  removal,  lymphatic  obstruction  due  to
umour  cell  embolism,  the  presence  of  a  sentinel  lymph
ode  in  the  neck,26 insufﬁcient  histopathological  analysis
nd  haematogenous  dissemination.
Recurrences  were  more  frequent  in  the  patient  group
ith  positive  sentinel  lymph  node  results  (22.7%)  than  in  that
f  negative  sentinel  lymph  node  results  (13.63%),  although
o  statistically  signiﬁcant  differences  were  obtained.  In  our
tudy  the  rate  of  local  recurrence  following  lymphadenec-
omy  after  a positive  sentinel  lymph  node  was  13.6%,  a
gure  in  the  range  of  that  published  in  other  studies  which
ould  vary  between  0  and  20%.8,27 However,  the  rate  of  local
ecurrence  after  a  lymphadenectomy  of  clinically  palpable
odes  ranged  between  20%  and  50%.27--29 It is  difﬁcult  to
ifferentiate  whether  greater  regional  control  is  associated
ith  the  lymphadenectomy  performed  after  a positive  sen-
inel  lymph  node  result.  Another  study27 compared  2  patient
roups  with  positive  sentinel  lymph  nodes  retrospectively
rom  different  hospitals;  a  lymphadenectomy  had  been  per-
ormed  on  several  of  them.  The  authors  did  not  ﬁnd  any
igniﬁcant  differences  in  terms  of  survival  between  both
roups.  We  would  highlight  that  in  our  study  only  2  patients
f  the  22  with  positive  sentinel  lymph  nodes  presented  other
ffected  lymph  nodes  (11%)  in  the  lymphadenectomy,  and
mong  those  who  presented  with  negative  lymphadenec-
omy,  another  2  patients  (13%)  developed  local  recurrence.
hese  results  raised  doubts  as  to  the  ultimate  effectiveness
f  lymphadenectomy.
With  regard  to  sample  mortality,  3  deaths  occurred  (4.3%)
hich  were  directly  related  to  the  melanoma  during  an
verage  follow-up  period  of  95  months.  This  percentage  is
lightly  lower  than  that  of  other  seriess14,15 where  mortality
s  around  8%.  This  difference  could  be  explained  by  the  high
ercentage  (23.5%)  of  patients  included  in  our  sample  who
ere  in  the  initial  stages  of  the  disease.  This  percentage
as  also  above  that  of  the  before-mentioned  series  where
t  was  around  4%.  The  sentinel  lymph  node  biopsy  result  is
onsidered  the  most  speciﬁc  and  sensitive  prognostic  factor
or  disease-free  and  overall  survival.20 In  our  study,  however,
e  found  there  were  no  statistically  signiﬁcant  differences
n  terms  of  mortality  between  patients  with  positive  and
egative  sentinel  lymph  nodes.  This  may  be  explained  by
he  low  number  of  recorded  incidences.
The  frequency  of  postoperative  complications  (seroma,
nfection)  observed  in  our  study  was  similar  to  that  of  other
tudies,  in  terms  of  morbidity  related  to  sentinel  lymph
ode  analysis,30 with  a clear  difference  noted  between  the
econdary  effects  associated  with  the  sentinel  lymph  node
iopsy  compared  with  lymphadenectomy,  where  results
ere  statistically  signiﬁcant.
We  have  shared  our  8  year  experience  in  our  hospital
ith  sentinel  lymph  node  biopsy  in  melanoma  patients  and
bserved  that  this  study  was  subject  to  several  limitations
uch  as:  sample  size;  scarcity  of  recorded  data  associated
ith  the  sample’s  high  survival  rate  and  the  fact  that  data
ollection  was  retrospective.
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onclusion
he  sentinel  lymph  node  biopsy  in  melanoma  patients  offers
seful  information  about  the  lymphatic  dissemination  of
elanoma  and  allows  an  approximation  to  the  regional  stag-
ng,  sparing  the  secondary  effects  of  lymphadenectomy.
owever,  studies  with  larger  sample  sizes  and  longer  follow-
p  periods  will  be  necessary  to  conﬁrm  the  validity  of
entinel  lymph  node  biopsy  in  melanoma  patients,  and  espe-
ially  of  lymphadenectomy  in  patients  with  positive  sentinel
ymph  node  biopsy.
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